体外成熟卵母细胞与常规IVF在高窦卵泡计数不孕女性中的随机非劣效试验
该单中心随机对照非劣效试验纳入546例高窦卵泡计数(≥24个)不孕女性,比较一个周期IVM与常规IVF的活产率。首次胚胎移植后活产率IVM组35.2%、IVF组43.2%,绝对风险差-8.1%(95%CI -16.6%, 0.5%),未能证明IVM非劣于IVF。
要点
- 高窦卵泡计数女性中,IVM组首次移植活产率35.2%,IVF组43.2%。
- 绝对风险差-8.1%(95%CI -16.6%, 0.5%),未达-10%非劣效界值。
- IVM组无卵巢过度刺激综合征发生,IVF组有2例。
核心结论
- 在高窦卵泡计数不孕女性中,一个周期IVM相比常规IVF未能证明活产率非劣效。
研究设计与样本
- 单中心随机对照非劣效试验,2018年1月至2019年4月在越南学术不孕中心开展,共546例高窦卵泡计数(双侧卵巢≥24个卵泡)不孕女性随机分为IVM组(n=273)和IVF组(n=273)。
主要发现
- 首次胚胎移植后活产:IVM组96例(35.2%),IVF组118例(43.2%),绝对风险差-8.1%(95%CI -16.6%, 0.5%)。
- 随机化后12个月累积持续妊娠率:IVM组44.0%,IVF组62.6%,绝对风险差-18.7%(95%CI -27.3%, -10.1%)。
- 卵巢过度刺激综合征:IVM组0例,IVF组2例。
- 妊娠并发症、产科和围产期并发症、早产、出生体重及新生儿并发症在两组间无统计学显著差异。
关键数值与推荐
- 非劣效界值为-10%。
- 高窦卵泡计数定义为双侧卵巢卵泡数≥24个。
临床怎么用
- IVM可作为部分寻求温和ART方案女性的可行且安全替代选择,但累积结局提示其可能劣于IVF。
- 临床决策时应考虑IVM的累积成功率可能低于常规IVF。
局限性
- 研究为开放标签设计。
- 结果仅适用于采用本研究中预成熟步骤方案的IVM。
- 单一种族人群限制了外部推广性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is one cycle of IVM non-inferior to one cycle of conventional in IVF with respect to live birth rates in women with high antral follicle counts (AFCs)? SUMMARY ANSWER: We could not demonstrate non-inferiority of IVM compared with IVF. WHAT IS KNOWN ALREADY: IVF with ovarian hyperstimulation has limitations in some subgroups of women at high risk of ovarian stimulation, such as those with polycystic ovary syndrome. IVM is an alternative ART for these women. IVM may be a feasible alternative to IVF in women with a high AFC, but there is a lack of data from randomized clinical trials comparing IVM with IVF in women at high risk of ovarian hyperstimulation syndrome. STUDY DESIGN, SIZE, DURATION: This single-center, randomized, controlled non-inferiority trial was conducted at an academic infertility center in Vietnam from January 2018 to April 2019. PARTICIPANTS/MATERIALS, SETTING, METHODS: In total, 546 women with an indication for ART and a high AFC (≥24 follicles in both ovaries) were randomized to the IVM (n = 273) group or the IVF (n = 273) group; each underwent one cycle of IVM with a prematuration step versus one cycle of IVF using a standard gonadotropin-releasing hormone antagonist protocol with gonadotropin-releasing hormone agonist triggering. The primary endpoint was live birth rate after the first embryo transfer. The non-inferiority margin for IVM versus IVF was -10%. MAIN RESULTS AND THE ROLE OF CHANCE: Live birth after the first embryo transfer occurred in 96 women (35.2%) in the IVM group and 118 women (43.2%) in the IVF group (absolute risk difference -8.1%; 95% confidence interval (CI) -16.6%, 0.5%). Cumulative ongoing pregnancy rates at 12 months after randomization were 44.0% in the IVM group and 62.6% in the IVF group (absolute risk difference -18.7%; 95% CI -27.3%, -10.1%). Ovarian hyperstimulation syndrome did not occur in the IVM group, versus two cases in the IVF group. There were no statistically significant differences between the IVM and IVF groups with respect to the occurrence of pregnancy complications, obstetric and perinatal complications, preterm delivery, birth weight and neonatal complications. LIMITATIONS, REASONS FOR CAUTION: The main limitation of the study was its open-label design. In addition, the findings are only applicable to IVM conducted using the prematuration step protocol used in this study. Finally, the single ethnicity population limits the external generalizability of the findings. WIDER IMPLICATIONS OF THE FINDINGS: Our randomized clinical trial compares live birth rates after IVM and IVF. Although IVM is a viable and safe alternative to IVF that may be suitable for some women seeking a mild ART approach, the current study findings approach inferiority for IVM compared with IVF when cumulative outcomes are considered. Future research should incorporate multiple cycles of IVM in the study design to estimate cumulative fertility outcomes and better inform clinical decision-making. STUDY FUNDING/COMPETING INTEREST(S): This work was partly supported by Ferring grant number 000323 and funded by the Vietnam National Foundation for Science and Technology Development (NAFOSTED) and by the Fund for Research Flanders (FWO). LNV has received speaker and conference fees from Merck, grant, speaker and conference fees from Merck Sharpe and Dohme, and speaker, conference and scientific board fees from Ferring; TMH has received speaker fees from Merck, Merck Sharp and Dohme, and Ferring; RJN has received conference and scientific board fees from Ferring, is a minor shareholder in an IVF company, and receives grant funding from the National Health and Medical Research Council (NHMRC) of Australia; BWM has acted as a paid consultant to Merck, ObsEva and Guerbet, and is the recipient of grant money from an NHMRC Investigator Grant; RBG reports grants and fellowships from the NHMRC of Australia; JS reports lecture fees from Ferring Pharmaceuticals, Biomérieux, Besins Female Healthcare and Merck, grants from Fund for Research Flanders (FWO), and is co-inventor on granted patents on CAPA-IVM methodology in the US (US10392601B2) and Europe (EP3234112B1); TDP, VQD, VNAH, NHG, AHL, THP and RW have no financial relationships with any organizations that might have an interest in the submitted work in the previous three years, and no other relationships or activities that could appear to have influenced the submitted work. TRIAL REGISTRATION NUMBER: NCT03405701 (www.clinicaltrials.gov). TRIAL REGISTRATION DATE: 16 January 2018. DATE OF FIRST PATENT’S ENROLMENT: 25 January 2018.
引用
- Vuong LN, Ho VNA, Ho TM, et al. In-vitro maturation of oocytes versus conventional IVF in women with infertility and a high antral follicle count: a randomized non-inferiority controlled trial. Hum Reprod. 2020. PMID: 32974672. doi:10.1093/humrep/deaa240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。